Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.87 USD
-0.01 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.87 0.00 (-0.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Adaptimmune Therapeutics PLC [ADAP]
Reports for Purchase
Showing records 1 - 20 ( 126 total )
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
A Newly Minted Commercial-Stage Company; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Breaking Ground in Cell Therapy to Treat Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
A Leader in Cell Therapy for Solid Tumors; Initiate With Buy and a $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Ovarian Cancer Trial Posted on Clinicaltrials.gov
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SURPASS Data Support a Pipeline in a Product Against Solid Tumors--PT $10
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SURPASSing the Solid Tumor Challenge with the Second Gen TCR: Virtual Event During ESMO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T